A Phase II Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First‐Line Treatment of Pancreatic Adenocarcinoma

LESSONS LEARNED. The safety profile in the gemcitabine/simtuzumab group was similar to that in the gemcitabine/placebo group. The addition of simtuzumab to gemcitabine does not improve clinical outcomes in patients with metastatic pancreatic adenocarcinoma. BACKGROUND. The humanized IgG4 monoclonal...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Benson, Al B., Wainberg, Zev A., Hecht, J. Randolph, Vyushkov, Dmitry, Dong, Hua, Bendell, Johanna, Kudrik, Fred
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2017
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5344644/
https://ncbi.nlm.nih.gov/pubmed/28246206
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0024
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados